---
figid: PMC7274131__fimmu-11-01088-g0001
figtitle: Rationale of PD-1/PD-L1 inhibitors
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC7274131
filename: fimmu-11-01088-g0001.jpg
figlink: pmc/articles/PMC7274131/figure/F1/
number: F1
caption: The rationale of PD-1/PD-L1 inhibitors. In tumor tissue, PD-1 interacts with
  PD-L1 or PD-L2 to mediate significant immune suppression. PD-1/PD-L1 inhibitors
  binds to corresponding target, thus blocking the PD-1/PD-L1 signaling pathway and
  markedly enhancing T cell function and the anti-tumor immunity.
papertitle: 'Looking for the Optimal PD-1/PD-L1 Inhibitor in Cancer Treatment: A Comparison
  in Basic Structure, Function, and Clinical Practice.'
reftext: Yu Chen, et al. Front Immunol. 2020;11:1088.
year: '2020'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9596228
figid_alias: PMC7274131__F1
figtype: Figure
redirect_from: /figures/PMC7274131__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7274131__fimmu-11-01088-g0001.html
  '@type': Dataset
  description: The rationale of PD-1/PD-L1 inhibitors. In tumor tissue, PD-1 interacts
    with PD-L1 or PD-L2 to mediate significant immune suppression. PD-1/PD-L1 inhibitors
    binds to corresponding target, thus blocking the PD-1/PD-L1 signaling pathway
    and markedly enhancing T cell function and the anti-tumor immunity.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PDCD1
  - RPL17
  - RPL17-C18orf32
  - CD80
  - CD274
  - PDCD1LG2
  - SNCA
  - SPATA2
---
